VTAK News & Events

Catheter Precision announced it received shareholder approval on April 15th of the definitive agreement to acquire Fly Flyte, executed on March 9. The March 9th transaction establishes Flyte as a wholly owned operating subsidiary. With full ownership complete: 100% of Flyte's revenue and operations are now consolidated into VTAK; Direct exposure to operating performance and cash flow; Full control of capital allocation, fleet expansion, and growth strategy.

Catheter Precision announced that it has engaged a strategic advisor to formally market for sale its cardiac electrophysiology business. This strategic initiative is designed to create shareholder value by monetizing the company's legacy medical device assets while sharpening its focus on the Flyte aviation platform.

Catheter Precision announced the official launch of Flyte Hops Florida, expanding Flyte's regional aviation network from its original New York-based service to now providing multiple aircraft along the entire East Coast from Maine to Florida. As previously announced, Flyte is a wholly-owned subsidiary of the company. The launch follows a recent soft operational rollout in Florida, which occurred while one of Flyte's Cirrus Vision Jets was undergoing routine scheduled maintenance in the region. During that brief period, Flyte generated more than $160,000 of inbound flight bookings on a single aircraft without marketing or promotional activity, demonstrating strong organic demand in the Florida market and beyond. Flyte is executing a fleet expansion strategy designed to replicate its regional air-mobility model across multiple high-demand U.S. markets, with at least five Cirrus Vision Jets expected to be in operation by Memorial Day 2026. Following the completion of its East Coast network, Flyte plans to expand operations into California and Texas in 2026 as part of a broader multi-region rollout strategy designed to replicate the company's model across major U.S. travel corridors.